Difference between revisions of "Malignant pleural mesothelioma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - ", et al. " to " et al. ")
(added regimen & variant labels)
Line 3: Line 3:
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
  
 +
{| class="wikitable" style="float:right; margin-right: 5px;"
 +
|-
 +
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
 +
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]]  |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
 +
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
  
 
=First-line therapy=
 
=First-line therapy=
  
−
==Active symptom control==
+
==Active symptom control {{#subobject:c39110|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:e5383|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 22: Line 31:
 
# Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18486741 PubMed]
 
# Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2431123 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18486741 PubMed]
  
−
==Carboplatin (Paraplatin) & Pemetrexed (Alimta)==
+
==Carboplatin (Paraplatin) & Pemetrexed (Alimta) {{#subobject:2feba8|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:395626|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 48: Line 61:
 
# Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. [http://annonc.oxfordjournals.org/content/19/2/370.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18156144 PubMed]
 
# Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. [http://annonc.oxfordjournals.org/content/19/2/370.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18156144 PubMed]
  
−
==Cisplatin (Platinol)==
+
==Cisplatin (Platinol) {{#subobject:82fdeb|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:7f0357|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 65: Line 82:
 
# Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12860938 PubMed]
 
# Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. [http://jco.ascopubs.org/content/21/14/2636.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12860938 PubMed]
  
−
==Cisplatin (Platinol) & Gemcitabine (Gemzar)==
+
==Cisplatin (Platinol) & Gemcitabine (Gemzar) {{#subobject:9e4c22|Regimen=1}}==
−
===Regimen #1, Nowak et al. 2002===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen #1, Nowak et al. 2002 {{#subobject:15fbf7|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 85: Line 106:
 
*[[antiemesis|5HT-3 antagonists, Dexamethasone (Decadron), and/or phenothiazines]] for antiemesis PO or by rectal suppository for 3-5 days after cisplatin
 
*[[antiemesis|5HT-3 antagonists, Dexamethasone (Decadron), and/or phenothiazines]] for antiemesis PO or by rectal suppository for 3-5 days after cisplatin
  
−
===Regimen #2, van Haarst et al. 2002===
+
===Regimen #2, van Haarst et al. 2002 {{#subobject:4dfb66|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 107: Line 128:
 
# Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. [http://www.nature.com/bjc/journal/v87/n5/full/6600505a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12189542 PubMed]
 
# Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. [http://www.nature.com/bjc/journal/v87/n5/full/6600505a.html link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12189542 PubMed]
  
−
==Cisplatin (Platinol) & Pemetrexed (Alimta)==
+
==Cisplatin (Platinol) & Pemetrexed (Alimta) {{#subobject:c2805d|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:3b6a3e|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 131: Line 156:
 
# Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15824080 PubMed]
 
# Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. [http://annonc.oxfordjournals.org/content/16/6/923.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15824080 PubMed]
  
−
==Pemetrexed (Alimta)==
+
==Pemetrexed (Alimta) {{#subobject:d9af60|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:4599ac|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 153: Line 182:
 
# Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. [http://journals.lww.com/jto/Fulltext/2008/07000/Single_Agent_Pemetrexed_for_Chemonaive_and.12.aspx link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18594323 PubMed]
 
# Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. [http://journals.lww.com/jto/Fulltext/2008/07000/Single_Agent_Pemetrexed_for_Chemonaive_and.12.aspx link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18594323 PubMed]
  
−
==Vinorelbine (Navelbine)==
+
==Vinorelbine (Navelbine) {{#subobject:9ec507|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:181640|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 170: Line 203:
  
 
=Second-line therapy=
 
=Second-line therapy=
−
==Best supportive care==
+
==Best supportive care {{#subobject:28910a|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:db813|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 185: Line 222:
 
# Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed]
 
# Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed]
  
−
==Gemcitabine (Gemzar)==
+
==Gemcitabine (Gemzar) {{#subobject:cc9029|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 
''Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists [[Gemcitabine (Gemzar)]] as a second-line monotherapy treatment option, but the listed reference did not provide details about its administration.  No primary reference could be found for [[Gemcitabine (Gemzar)]] monotherapy in this setting.''
 
''Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists [[Gemcitabine (Gemzar)]] as a second-line monotherapy treatment option, but the listed reference did not provide details about its administration.  No primary reference could be found for [[Gemcitabine (Gemzar)]] monotherapy in this setting.''
  
−
==Pemetrexed (Alimta)==
+
==Pemetrexed (Alimta) {{#subobject:7b23e|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:dfdd1|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 210: Line 255:
 
# Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed]
 
# Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. [http://jco.ascopubs.org/content/26/10/1698.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18375898 PubMed]
  
−
==Vinorelbine (Navelbine)==
+
==Vinorelbine (Navelbine) {{#subobject:4e5cff|Regimen=1}}==
−
===Regimen===
+
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#toc|back to top]]
 +
|}
 +
===Regimen {{#subobject:c46485|Variant=1}}===
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  

Revision as of 06:32, 9 February 2015

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

19 regimens on this page
33 variants on this page


First-line therapy

Active symptom control

back to top

Regimen

Level of Evidence: Phase III

No antineoplastic treatment; used as a comparator arm and here for reference purposes only.

References

  1. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. link to original article contains verified protocol PubMed

Carboplatin (Paraplatin) & Pemetrexed (Alimta)

back to top

Regimen

Level of Evidence: Phase II

21-day cycles; up to 9 cycles in Castagneto et al. 2008

Supportive medications (varies depending on reference):

  • Folic acid 350-600 mcg PO daily, starting at least 1 week before pemetrexed, to continue throughout therapy
  • Cyanocobalamin (Vitamin B12) 1000 mcg IM once at least 1 week before pemetrexed, then 1000 mcg to be given every 9 weeks thereafter
  • Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after pemetrexed
  • No NSAIDs (nonsteroidal anti-inflammatory drugs) for 2 days (5 days for NSAIDs with longer half-lives) before or after pemetrexed

References

  1. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006 Mar 20;24(9):1443-8. link to original article contains verified protocol PubMed
  2. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20. link to original article contains verified protocol PubMed

Cisplatin (Platinol)

back to top

Regimen

Level of Evidence: Phase III

21-day cycles

References

  1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. link to original article contains verified protocol PubMed

Cisplatin (Platinol) & Gemcitabine (Gemzar)

back to top

Regimen #1, Nowak et al. 2002

Level of Evidence: Phase II

28-day cycles x up to 6 cycles

Supportive medications:

Regimen #2, van Haarst et al. 2002

Level of Evidence: Phase II

21-day cycles x up to 6 cycles

Supportive medications:

References

  1. van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002 Feb 1;86(3):342-5. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002 Aug 27;87(5):491-6. link to original article contains verified protocol PubMed

Cisplatin (Platinol) & Pemetrexed (Alimta)

back to top

Regimen

Level of Evidence: Phase III

21-day cycles

Supportive medications:

  • Folic acid 350-1000 mcg PO daily, starting 1-3 weeks before pemetrexed, to continue throughout therapy
  • Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1-3 weeks before pemetrexed, then 1000 mcg to be given every 9 weeks thereafter
  • Dexamethasone (Decadron) (dose not specified by reference) the day before, the day of, and day after pemetrexed

References

  1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44. link to original article contains verified protocol PubMed
  2. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11. link to original article PubMed

Pemetrexed (Alimta)

back to top

Regimen

Level of Evidence: Phase II

21-day cycles

Supportive medications:

  • Folic acid 350-600 mcg PO daily, starting 1-2 weeks before pemetrexed, to continue throughout therapy and at least 3 weeks after the last dose of pemetrexed
  • Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1-2 weeks before pemetrexed, then 1000 mcg to be given every 9 weeks thereafter while continuing on pemetrexed therapy
  • Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after pemetrexed

References

  1. Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008 Jul;3(7):764-71. link to original article contains verified protocol PubMed

Vinorelbine (Navelbine)

back to top

Regimen

Level of Evidence: Phase III

Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists the Vinorelbine (Navelbine) dosage as 25-30 mg/m2. No primary reference could be found for the 25 mg/m2 dosage.

  • Vinorelbine (Navelbine) 30 mg/m2 IV weekly x 12 weeks, with a 2-week treatment-free gap between the 6th and 7th doses

References

  1. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 May 17;371(9625):1685-94. link to original article contains verified protocol PubMed

Second-line therapy

Best supportive care

back to top

Regimen

Level of Evidence: Phase III

No antineoplastic treatment; used as a comparator arm and here for reference purposes only.

References

  1. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. link to original article contains verified protocol PubMed

Gemcitabine (Gemzar)

back to top

Note: The NCCN, Malignant Pleural Mesothelioma version 2.2012, lists Gemcitabine (Gemzar) as a second-line monotherapy treatment option, but the listed reference did not provide details about its administration. No primary reference could be found for Gemcitabine (Gemzar) monotherapy in this setting.

Pemetrexed (Alimta)

back to top

Regimen

Level of Evidence: Phase III

21-day cycles x 8 or more cycles

Supportive medications:

  • Folic acid 350-1000 mcg PO daily, starting 1-2 weeks before pemetrexed, to continue throughout therapy and at least 3 weeks after the last dose of pemetrexed
  • Cyanocobalamin (Vitamin B12) 1000 mcg IM once 1-2 weeks before pemetrexed, then 1000 mcg to be given every 9 weeks thereafter while continuing on pemetrexed therapy
  • Dexamethasone (Decadron) 4 mg PO BID the day before, the day of, and day after pemetrexed

References

  1. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008 Apr 1;26(10):1698-704. link to original article contains verified protocol PubMed

Vinorelbine (Navelbine)

back to top

Regimen

Level of Evidence: Phase II

42-day cycles

References

  1. Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009 Jan;63(1):94-7. Epub 2008 May 16. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_pleural_mesothelioma&oldid=7109"